Clinical Trial · NCT06813742

18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma

Overview

The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.

Sponsor

First Affiliated Hospital of Zhejiang University

Contacts

Peipei Wang, MD (CONTACT)

wpp199411@163.com

86 18511395988

ClinicalTrials.gov

NCT06813742

Drug / Compound

MFBG

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Eligibility

Inclusion

Clinically diagnosed patients with pheochromocytoma;

Exclusion

Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;
Uncontrolled hypertension or high-risk BP (i.e., systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg);
Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.
Patients with mental disorders or primary affective disorders;
Allergy to imaging agents;